Rapid Readouts: Phase 2 JULIET Trial

Jan 26, 2021

Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center

Related Videos

Jorge E. Cortes, MD

Bradley W. Christensen, MD

Veronika Bachanova, MD, PhD

Eunice Wang, MD

Expert on AML

Expert on AML

Craig Sauter, MD

Experts on AML

Expert on AML

Expert on urothelial carcinoma

Related Content

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Related Content

Anne Kerber

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

March 31st 2023

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Image Credit: ©freshidea - stock.adobe.com

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Allison C. Rosenthal, DO

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Axi-Cel Elicits Benefit in LBCL | Image Credit: ©Dr_Microbe - stock.adobe.com

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

Eunice Wang, MD

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Latest Conference Coverage

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.